Centre for Advanced Discovery and Experimental Therapeutics (CADET)  

Our innovative £3m Centre for Advanced Discovery and Experimental Therapeutics is dedicated to developing new drugs to prevent and treat major diseases such as diabetes and pre-eclampsia. 

The facility opened in 2010 and houses state-of-the-art equipment for analysing tissue and blood samples provided by patients. 

Lead by Professor Garth Cooper, researchers at CADET carry out large scale studies of the proteins (proteomics) and chemical processes (metabolomics) in tissues and blood, to help improve the way major diseases are diagnosed and treated. 

CADET is the first UK facility to combine a tissue bank, proteomics and metabolomics laboratories all on one site.  It also has a team of bioinformatics experts who analyse all the data produced in experiments to identify patterns and trends which could lead to new methods of diagnosis and treatments. 

Professor Cooper is a world-leading expert in this area, and joined the Biomedical Research Centre from New Zealand in 2011. He has published over 200 articles in leading journals, as well as being named as inventor on more than 40 US and European patents.

He discovered the hormone amylin while studying for his doctorate in the UK and went on to invent amylin-replacement therapy for diabetes and founded the NASDAQ-listed US company Amylin Pharmaceuticals. 

Please visit the CADET Contact Us page for contact details and directions to CADET

“CADET is more than just a facility, it's a different philosophy and approach to finding out what causes diseases, how they progress in the body and how we can prevent or treat them.”

“This was the major attraction for me in coming to Manchester, where CADET is the link between laboratory scientists at the University and patients on the hospital wards.”

Professor Garth Cooper, CADET Director